RelayHealth and McKesson Specialty Health Administer First Class-Wide Transmucosal Immediate Release Fentanyl REMS Program

ATLANTA--(BUSINESS WIRE)--The first class-wide risk evaluation and mitigation strategies (REMS) program for the transmucosal immediate-release fentanyl (TIRF) class of medications was approved in December by the Food and Drug Administration (FDA) and will be administered by RelayHealth and McKesson Specialty Health. The TIRF REMS Access program covers the TIRF medications, which are fast-acting opioid pain relievers used to manage breakthrough pain in opioid-tolerant cancer patients.